Duloxetine Capsule, Delayed Release
Product Images NDC 70518-1054

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 70518-1054). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Duloxetine 30mg 70518 1054 01)

Label for Duloxetine 30 mg delayed-release capsules, quantity 90, repackaged by RemedyRepack Inc. The label includes the NDC number 70518-1054-01, manufacturer Ajanta Pharma Ltd. in India, and storage instructions at 20-25°C with allowed excursions. Directions refer to the package insert.*

FDA Label Image

Mm3 (Duloxetine 30mg 70518 1054 02)

Label for Duloxetine 30 mg delayed-release capsules, quantity 30, repackaged by RemedyRepack Inc. The label includes the NDC number 70518-1054-02, manufacturer Ajanta Pharma Ltd., and storage instructions. It is marked Rx only and directs users to see the package insert for directions.*

FDA Label Image

Mm4 (Duloxetine 30mg 70518 1054 03)

Duloxetine 30 mg delayed-release capsules packaging label, showing a quantity of 60. The label includes the drug name, strength, dosage form, NDC number 70518-1054-03, manufacturer Ajanta Pharma Ltd in India, and repackacker RemedyRepack Inc. Directions reference the package insert, and storage temperature guidelines are provided. The label also contains a barcode and a QR code.*

FDA Label Image

Mm5 (Duloxetine 30mg 70518 1054 04)

Duloxetine 30 mg delayed-release capsules label by RemedyRepack Inc. The label indicates a quantity of 30 capsules, with dosage form as capsules. It includes NDC 70518-1054-04, manufacturing details from Ajanta Pharma Ltd., India, and storage instructions at 20-25°C. The label also notes repackaging information by RemedyRepack Inc., Indiana, PA.*

FDA Label Image

Mm6 (Duloxetine 30mg 70518 1054 05)

Label for Duloxetine 30 mg delayed-release capsule, quantity 1, repackaged by RemedyRepack Inc. The label includes NDC 70518-1054-05 and manufacturing details from Ajanta Pharma Ltd., India. Storage instructions specify 20-25°C with permitted excursions to 15-30°C, and users are directed to see the package insert for use directions.*

FDA Label Image

Mm7 (Duloxetine 30mg 70518 1054 06)

Duloxetine 30 mg delayed-release capsules packaging label showing a quantity of 30 units. The label indicates the product is prescription only, manufactured by Ajanta Pharma Ltd in India, and repackaged by RemedyRepack Inc. in Indiana, PA. Storage instructions and a barcode with a QR code are also visible.*

FDA Label Image

Duloxetine 30mg 70518 1054 07

Duloxetine 30 mg delayed-release capsules, quantity 30, in packaging labeled with RemedyRepack Inc. The label includes manufacturing details by Ajanta Pharma Ltd, India, barcodes, and a QR code. It specifies storage instructions and indicates the product is prescription only.*

FDA Label Image

Duloxetine 30mg 70518 1054 08

Duloxetine 30 mg delayed-release capsules packaging label showing a quantity of 30 capsules. The label includes the NDC number 70518-1054-08 and indicates the product is RX only. Manufactured by Ajanta Pharma Ltd., India, and repackaged by RemedyRepack Inc. in Indiana, USA. Storage instructions and a QR code are also visible.*

FDA Label Image

Duloxetine 30mg 70518 1054 09

Duloxetine 30 mg delayed-release capsules label from RemedyRepack Inc. The package contains 90 capsules. Label includes NDC 70518-1054-09, manufacturing by Ajanta Pharma Ltd., India, and storage directions to keep between 20-25°C with permitted excursions to 15-30°C. Directions for use refer to the package insert.*

FDA Label Image

Remedy_label (Remedy Label)

Duloxetine 30 mg delayed-release capsules packaging label from RemedyRepack Inc. The label indicates a quantity of 30 capsules. It includes regulatory information such as the Rx only status, NDC number 70518-1054-00, manufacturer Ajanta Pharma Ltd. in India, and storage instructions. The label features the RemedyRepack logo and barcode.*

FDA Label Image

Figure1 (Duloxetine Fig1)

A line graph showing the proportion of patients with relapse over time from randomization in days. The graph compares two treatments: Placebo and Duloxetine. The y-axis represents the proportion of patients with relapse, ranging from 0.0 to 1.0. The x-axis shows time from 0 to 250 days. Duloxetine shows a consistently lower proportion of relapse compared to Placebo over the study period.*

FDA Label Image

Figure10 (Duloxetine Fig10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It contrasts results for placebo and Duloxetine 60/120 mg once daily, with Duloxetine showing a higher percentage of patient improvement across various pain improvement thresholds.*

FDA Label Image

Figure2 (Duloxetine Fig2)

A line graph comparing the proportion of patients with relapse over time (in days) from randomization for two treatments: placebo and duloxetine. The x-axis represents time in days up to about 270, and the y-axis shows the proportion of patients with relapse, ranging from 0 to 1. The placebo group is represented by a dashed line, showing a higher relapse proportion earlier, while the duloxetine group is a solid line with a lower and slower increase in relapse proportion.*

FDA Label Image

Figure3 (Duloxetine Fig3)

A line chart showing the percentage of patients improved against percent improvement in pain from baseline. Four lines represent Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and Placebo, detailing patient response curves to these dosages compared to placebo over varying pain improvement percentages.*

FDA Label Image

Figure4 (Duloxetine Fig4)

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline for three groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and Placebo. The graph shows both duloxetine groups have higher percentages of patient improvement compared to placebo across pain improvement levels.*

FDA Label Image

Figure5 (Duloxetine Fig5)

A line graph depicting the percentage of patients improved against percent improvement in pain from baseline, comparing Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The y-axis shows the percentage of patients improved (0-100%), and the x-axis shows percent improvement in pain from baseline (0 to 100%). Duloxetine groups show higher improvement percentages than placebo across most pain improvement levels.*

FDA Label Image

Figure6 (Duloxetine Fig6)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at doses of 120 mg, 60 mg, and 20 mg once daily, compared to placebo. The graph tracks patient improvement across a range of pain reduction percentages from greater than 0 to 100.*

FDA Label Image

Figure8 (Duloxetine Fig8)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It shows two lines representing placebo and Duloxetine 60/120 mg once daily, with the y-axis labeled 'Percentage of Patients Improved' and x-axis labeled 'Percent Improvement in Pain from Baseline (BOCF)'.*

FDA Label Image

Figure9 (Duloxetine Fig9)

A line graph comparing the percentage of patients improved at various levels of percent improvement in pain from baseline (BOCF) between placebo and Duloxetine 60 mg once daily. The x-axis shows percent improvement in pain from >0 to 100%, while the y-axis shows the percentage of patients improved, ranging from 0 to 100%. Duloxetine shows a higher percentage of patients improved across most improvement levels compared to placebo.*

FDA Label Image

Structure (Duloxetine Structure)

Chemical structure of Duloxetine, showing its molecular framework with a benzene ring system, thiophene ring, and an amine group with hydrochloride salt (HCl). The image depicts the arrangement of atoms and bonds characteristic of Duloxetine.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.